Cellipont Bioservices Partners with Xiogenix to Enhance Client Access to Advanced Filling Systems

• Cellipont Bioservices and Xiogenix have partnered to integrate the Ares X20 fill-and-finish system into Cellipont’s offerings.

• The collaboration enhances precision and efficiency in cell therapy manufacturing processes.

Cellipont Bioservices, a cell therapy-focused Contract Development and Manufacturing Organization (CDMO), has announced a strategic partnership with Xiogenix, a biopharmaceutical technology innovator. The partnership introduces the advanced Ares X20 fill-and-finish system to Cellipont’s manufacturing capabilities, enabling more precise and efficient cell therapy product processing.

The Ares X20 system, developed by Xiogenix, offers automated formulation, precise temperature control, and high-throughput capabilities. It processes multiple containers in under five minutes while minimizing waste and ensuring consistent product quality. The system’s scalability and automation aim to streamline therapy production and accelerate market timelines.

“This partnership with Xiogenix marks another significant milestone for Cellipont Bioservices,” said Darren Head, CEO of Cellipont Bioservices. “We are committed to adopting advanced technologies that drive innovation and excellence in biopharmaceutical manufacturing. Through this collaboration with Xiogenix, we offer our clients access to advanced fill-and-finish system, enhancing our service offerings and delivering superior solutions.”

“We are thrilled to partner with Cellipont Bioservices to bring ourAres X20 fill and finish system to a broader range of clients,” said Rachel Bahr, CEO of Xiogenix. “This collaboration aligns with our mission to provide innovative solutions that enhance the efficiency and reliability of biopharmaceutical manufacturing. We look forward to seeing the positive impact this partnership will have on the industry.”